Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 trial comparing efficacy and safety of paclitaxel oral solution (RMX3001) with paclitaxel injection (Taxol®) in patients with advanced gastric cancer who failed previous treatment

Trial Profile

A phase 3 trial comparing efficacy and safety of paclitaxel oral solution (RMX3001) with paclitaxel injection (Taxol®) in patients with advanced gastric cancer who failed previous treatment

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxels (Primary) ; Paclitaxels (Primary)
  • Indications Gastric cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 13 Sep 2022 According to a HaiHe Biopharma media release, Marketing Authorization Application (MAA) for Paclitaxel Oral Solution (RMX3001) in gastric cancer (GC) has been accepted for review by the National Medical Products Administration-Center for Drug Evaluation (NMPA-CDE).
    • 13 Sep 2022 According to a HaiHe Biopharma media release, Professor Jin Li from Shanghai East Hospital and Professor Shukui Qin from Nanjing Jinling Hospital is the leading principal investigator of this study.
    • 13 Dec 2018 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top